Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
107 hedge funds and large institutions have $1.08B invested in Avidity Biosciences in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
54% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 26
0.47% less ownership
Funds ownership: 97.32% → 96.85% (-0.47%)
1% less capital invested
Capital invested by funds: $1.09B → $1.08B (-$13.7M)
4% less funds holding
Funds holding: 111 → 107 (-4)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
71% less call options, than puts
Call options by funds: $2K | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.9M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$5.96M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$21.8M |
| 2 |
Goldman Sachs
New York
|
-$5.59M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.26M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.95M |
| 5 |
5VM
5AM Venture Management
San Francisco,
California
|
-$3.94M |
RNAM Hedge Fund Activity: Q4 2021 in Review
107 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2021, worth a combined $1.08B — down 1.3% from $1.09B a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RNAM and 13 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 40 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $15.3M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $21.8M sold.
- 107 institutional investors held Avidity Biosciences (RNAM) as of Q4 2021, down from 111 in Q3 2021.
- Funds reported $1.08B of Avidity Biosciences stock for Q4 2021, down 1.3% quarter-over-quarter.
- 13 funds opened new Avidity Biosciences positions in Q4 2021 and 16 closed out, a net change of -3 holders.
- The largest Avidity Biosciences buyer in Q4 2021 was T. Rowe Price Associates, an estimated $15.3M added.
- The largest Avidity Biosciences seller in Q4 2021 was Perceptive Advisors, an estimated $21.8M sold.
Based on aggregated 13F filings for Q4 2021.